Comparison of the Effects of Magnesium Sulfate and Remifentanil on Hemodynamic Responses During Tracheal Extubation After Laparotomy: A Randomized Double-blinded Trial


Seyed Mojtaba Marashi 1 , Reza Hassan Nikkhouei 1 , Ali Movafegh 1 , Gita Shoeibi 1 , Shaqayeq Marashi 1 , *

1 Anesthesiology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

How to Cite: Marashi S M, Hassan Nikkhouei R, Movafegh A, Shoeibi G, Marashi S. Comparison of the Effects of Magnesium Sulfate and Remifentanil on Hemodynamic Responses During Tracheal Extubation After Laparotomy: A Randomized Double-blinded Trial, Anesth Pain Med. 2015 ; 5(4):e25276. doi: 10.5812/aapm.25276.


Anesthesiology and Pain Medicine: 5 (4); e25276
Published Online: August 26, 2015
Article Type: Research Article
Received: November 11, 2014
Revised: February 15, 2015
Accepted: April 12, 2015


Background: Because blood pressure and heart rate (HR) elevations during tracheal extubation are common, different medications have been studied to prevent such complications.

Objectives: To compare magnesium sulfate, remifentanil, and placebo regarding mean arterial pressure (MAP) and HR changes during/after tracheal extubation, in patients who underwent laparotomy.

Materials and Methods: In this randomized double-blinded trial, 120 patients undergoing laparotomy were evenly divided into three groups, including remifentanil (1 mcg/kg), magnesium sulfate (50 mg/kg), or normal saline, as placebo. Hemodynamic responses (MAP and HR) were documented at different times (before operation, during medication administration, immediately before extubation, immediately after extubation, and also 3, 5, and 10 minutes after extubation). The double burst time (DBT) was determined using neuromuscular monitoring, as time interval, between administration of reverse medication and DBT of 100%.

Results: The HR was significantly lower, immediately after extubation and 3, 5, and 10 minutes after extubation, in both magnesium and remifentanil groups, compared to normal saline (P < 0.001). The MAP was also lower in magnesium and remifentanil groups, immediately after extubation and 3 minutes after extubation, in comparison to the normal saline group (P < 0.001). Mean (± SD) DBT 100% was significantly higher in magnesium group (30.2 ± 15.3) vs. remifenatnil (13.6 ± 6.8) and normal saline (13.5 ± 8.2) groups (P < 0.001).

Conclusions: Both remifentanil and magnesium had favorable outcomes in preventing HR and MAP elevation after tracheal extubation. However, remifentanil was associated with more rapid regaining of consciousness and reversal of muscular relaxation.

1. Background

Tracheal extubation is an important part of general anesthesia, which can be associated with complications (1). Both cardiac and respiratory complications, associated with tracheal extubation, may lead to considerable morbidity and mortality (2). Cardiopulmonary adverse events resulted from tracheal extubation (12.6%) are three times more common when compared to those of endotracheal intubation and induction of general anesthesia (4.6%) (3).

The major adverse events associated with tracheal extubation include mechanical complications (such as trauma to the larynx) (4), cardiovascular complications [such as 10 - 30% increase in blood pressure (BP) and heart rate (HR) increase for 5 - 10 minutes] (5), respiratory complications (atelectasis, coughing, hypoxia and etc.) (6).

Documented beneficial effects of magnesium, as a selective blocker for calcium channels and N-methyl-d-aspartate (NMDA) receptor antagonist, have been the basis for multiple studies that have reported protective effects of this medication regarding hemodynamic responses, in patients undergoing general anesthesia (7, 8). Studies have noted that magnesium has an important role as vasodilator in arterioles, whereas this effect is minimal on venules, which result in improvement in cardiac output (9). This function is regulated mainly by blocking sympathetic system via inhibiting the release of catecholamines from the adrenal, as well as peripheral nerve endings (10). In addition, magnesium has beneficial effects on maintaining diastolic function and regulating sinus rhythm, during arrhythmias (11). Since magnesium is a vasodilator, it has been used in general anesthesia to decrease BP and prevent its elevation.

Remifentanil, as an anilidopiperidine opioid, has similar pharmacodynamic characteristics to other opioids, however with distinct pharmacokinetic properties (12). This is an effective medication for analgesia, considering its analgesic properties. Since it has no inhibitory effect on the local nervous system, it can be used during extubation (13). In comparison to fentanyl and alfentanil, remifentanil administration is associated with better control of hemodynamic responses during surgery and lower rate of respiratory depression. However, hypotension and bradycardia have been reported, when remifentanil is administered during surgery, and its effects, after extubation, are not completely understood (14).

As mentioned earlier, hemodynamic changes during extubation are common. Hence, medications have been used to prevent these unfavorable changes. Magnesium sulfate and remifentanil are two of the medications that may be used, although studies to determine their efficacy in this regard, as well as any other side effects resulted by using these agents are necessary.

2. Objectives

Here, we intended to compare the effects of remifentanil and magnesium on BP, as well as heart rate changes during tracheal extubation, in patients undergoing laparotomy under general anesthesia.

4. Results

Table 1 presents the baseline characteristics (age, gender, weight) of the patients. As shown, no significant differences were found, regarding baseline characteristics, between the three groups.

Table 1. Comparison of Age, Gender, and Weight in Laparotomy Patients who Received Remifentanil, Magnesium Sulfate, or Normal Saline a
Remifentanil Magnesium Sulfate Normal Saline P Value
Gender, Male52.5%45%47.5%0.79
Age, y43 (± 11.7)42.7 (± 10.5)38.7 (± 12.7)0.18
Weight, kg66.4 (± 10.8)68.4 (± 8.9)70.6 (± 10.2)0.17

a For each group: (n = 40).

Table 2 presents anesthesia-related variables. As shown, no significant differences were found regarding mean general anesthesia duration, total fentanyl dosage administered, time interval passed between fentanyl administration and studied medication administration, or time interval between studied medication administration and tracheal extubation, between the three groups.

Table 2. Comparison of General Anesthesia-Related Variables in Laparotomy Patients who Received Remifentanil, Magnesium Sulfate, or Normal Saline a
Remifentanil Magnesium Sulfate Normal Saline P Value
Anesthesia Duration, min108.4 (± 18.6)108.9 (± 11.8)106.7 (± 10.5)0.77
Total Fentanyl Dosage, mcg275 (± 45.3)278 (± 51.7)261.2 (± 57.1)0.28
Time Interval Between Fentanyl and Studied Medication Administration, min25.7 (± 16.9)33.9 (± 15.4)31 (± 19.70)0.1
Time Interval Between Studied Medication Administration and Tracheal Extubation, min16.4 (± 8)14.45 (± 3.1)14.9 (± 4.9)0.26

a For each group: (n = 40).

Regarding HR changes, recorded before starting the operation until 10 minutes after extubation, there was no significant difference between the three groups, until the time point recorded immediately before extubation. However, immediately after extubation and 3, 5, and 10 minutes after extubation, mean HR showed a significant decrease, in comparison to normal saline group (Table 3). However, analysis of the HR changes pattern, at different time points, showed that there was no significant difference between the groups, with respect to heart rate during follow-up period (P = 0.11).

Table 3. Comparison of Mean (± SD) Heart Rate at Different Time Points in Patients who Underwent Laparotomy and Received Remifentanil, Magnesium Sulfate, or Normal Saline a
Remifentanil Magnesium Sulfate Normal Saline P Value
Before Operation93.4 (± 17.6)87.6 (± 15.6)90.2 (± 14.3)0.26
Time 0 b79.2 (± 10.9)81.2 (± 15.8)78.7 (± 14.7)0.7
Immediately Before Extubation93.8 (± 17.3)98.2 (± 14.9)94.9 (± 14.9)0.74
Immediately After Extubation 95.4 (± 10.6)105.2 (± 16.4)111.03 (± 14.9)< 0.001
Minute 3 Post-Extubation85.2 (± 12.3)85.9 (±17.8)98.05 (± 13)< 0.001
Minute 5 Post-Extubation85.06 (± 12.8)85.2 (± 15.2)92.8 (± 11.7)< 0.001
Minute 10 Post-Extubation84.7 (± 12.8)85.7 (± 13.9)91.9 (± 12.1)< 0.001

a For each group: (n = 40).

b Time 0 = after putting the last stitch on the skin.

A similar pattern to HR changes was observed with regard to MAP. At follow-up time point before extubation, no significant difference was seen between the two groups. However, MAP was significantly lower in remifentanil and magnesium groups, compared to normal saline group, immediately after extubation, as well as at minute 3 after extubation. At minutes 5 and 10 post-extubation, again no difference was present between the groups. Two groups of remifentanil and magnesium were comparable regarding MAP changes (Table 4). Analysis of MAP changes pattern, at different time points, showed that there was no significant difference between the groups during follow-up period (P = 0.58).

Table 4. Comparison of Mean (± SD) Mean Arterial Pressure (MAP) at Different Time Points in Patients Underwent Laparotomy Who Received Remifentanil, Magnesium Sulfate, or Normal Saline a
Remifentanil Magnesium Sulfate Normal Saline P Value
Before Operation102.6 (± 16.7)100.2 (± 17.08)102.7 (± 10.6)0.69
Time 0 b94.3 (± 17.2)98.8 (± 11.4)92.7 (± 10.8)0.11
Immediately Before Extubation101.08 (± 14.6)103.1 (± 19.9)97.05 (± 13.7)0.23
Immediately After Extubation 104.9 (± 18.6)107.1 (± 9.9)119.1 (± 11.02)< 0.001
Minute 3 Post-Extubation105 (± 11.2)101.4 (± 8.5)111.08 (± 15.1)0.002
Minute 5 Post-Extubation102.2 (± 9.6)100.1 (± 9.1)100.7 (± 11.2)0.63
Minute 10 Post-Extubation99.8 (± 8.54)98.9 (± 9.05)98.9 (± 11.01)0.88

a For each group: (n = 40).

b Time 0 = after putting the last stitch on the skin.

Remifentanil and magnesium, both resulted in less severe coughing episodes, compared to normal saline. The frequencies of mild and moderate coughing were 82.5% and 10% in remifentanil group, 80% and 20% in magnesium group, and 40% and 52.5% in normal saline group, respectively. Severe cough was not reported in magnesium group, although it was reported in 7.5% of patients of normal saline and remifentanil groups (P < 0.001). However, no difference was detected between magnesium and remifentanil groups.

At 5 minutes after extubation, 60% of normal saline cases were alert and responsive; however, this percentage was 47.5% in remifentanil group and 25% in magnesium group (P = 0.004). Similar findings were noted at 15 minutes post-extubation time. Alertness and responsiveness was reported in 95% of normal saline patients, 72.5% of remifenatnil cases and in 60% of magnesium patients (P = 0.007).

Mean ± SD DBT 100% was significantly higher in magnesium group (30.2 ± 15.3) vs. remifenatnil (13.6 ± 6.8) and normal saline (13.5 ± 8.2) groups (P < 0.001).

5. Discussion

This study aimed to compare magnesium and remifentanil regarding their effects on hemodynamic responses during tracheal extubation, in patients undergoing laparotomy. The obtained findings showed that mean HR recorded a significant decrease, in both magnesium and remifentanil group, immediately after tracheal extubation. This trend continued until 10 minutes post-extubation. Likewise, MAP was significantly lower in magnesium and remifentanil groups, compared to normal saline group, after extubation. This continued just up to 3 minutes post-extubation, and then the three groups were similar regarding MAP. When the two groups of magnesium and remifentanil are compared, we did not detect differences between them in terms of HR or MAP. Administering magnesium and remifentanil, both resulted in less severe coughing episodes, in comparison to normal saline, although neither magnesium nor remifentanil had superiority to each other in decreasing coughing severity. However, regarding consciousness level, the patients who received just normal saline had higher rate of alertness and responsiveness at 5 and 15 minutes post-extubation than patients of remifentanil or magnesium groups.

The above core findings suggest that both magnesium and remifentanil have comparable effects on hemodynamic responses during and shortly after tracheal extubation. However, patients of remifentanil group had a better profile in regaining consciousness than magnesium group.

In a similar clinical trial, the effects of remifentanil (1 mcg/kg) or magnesium sulfate (30 mg/kg) were compared versus placebo, regarding SBP, DBP, HR and oxygen saturation in electroconvulsive therapy (7). The authors studied 20 patients for whom anesthesia was induced by thiopental (4 mg/kg). They reported that remifentanil and magnesium administration were associated with a significant attenuation of the increase in SBP. However, only remifentanil attenuated HR, not magnesium. It was concluded that, since magnesium had no effect on HR, this effect may be considered as an advantage, compared to remifentanil, in patients who needed electroconvulsive therapy. These findings are similar to ours, in terms of BP changes, as we observed that both remifentanil and magnesium prevented increases in MAP. Plus, we observed a similar effect on HR, which was not reported by the mentioned article in magnesium group. The advantage of magnesium is attributed to the fact that it may result in bradycardia, and similarly, we did not see bradycardia in our patients who received magnesium or remifentanil.

In a study to determine the hemodynamic responses after endotracheal intubation, magnesium sulfate and remifentanil were compared. Lim et al. (16) studied 80 patients who underwent general anesthesia and divided them to receive normal saline, magnesium sulfate (50 mg/kg), remifentanil (1 mcg/kg), or a combination of 25 mg/kg magnesium sulfate and 0.5 mcg/kg remifentanil, which were administered half a minute before induction of anesthesia, with propofol and succinylcholine. The results showed that SBP changes of patients, who received magnesium, remifentanil, or combination of these two agents, were lower, immediately after intubation than those of the normal saline group. The SBP in magnesium and magnesium/remifentanil groups showed an increase in relation to baseline recording, although SBP alone, in remifentanil group, decreased from that at the baseline, immediately after intubation. In contrast to our results, where we observed a decrease in HR in both remifentanil and magnesium groups, Lim et al. found an increase in HR of magnesium group, with a decrease of heart rate in remifentanil group. They concluded that magnesium was associated with increase in SBP and tachycardia after intubation, whereas remifentanil resulted in SBP drop and bradycardia (16).

Kim et al. (17) studied remifentanil infusion effects on hemodynamic responses and coughing during extubation in postoperative (major abdominal surgery) intensive care unit patients, in a randomized clinical trial. They reported that MAP, HR and coughing severity did not differ between the two groups during extubation. The only significant difference was related to the time from discontinuation of propofol infusion to extubation, which was significantly longer in the remifentanil group, compared to control group. Wu et al. (18) investigated the efficacy of different dosages of remifentanil (0.05, 0.1, and 0.2 mcg/kg) for attenuating cardiovascular response to tracheal extubation, after general anesthesia, in 164 surgical (upper abdominal surgery) patients. They concluded that remifentanil at 0.1 mcg/kg was the ideal dose to prevent hemodynamic response to tracheal extubation.

As the prevention of MAP and HR elevation, after tracheal extubation, is considered in anesthesiology, both magnesium and remifentanil had comparable effects in prevention of adverse hemodynamic responses. Regarding the faster regaining of consciousness and reversal of muscular relaxation, remifentanil was superior to magnesium. Future studies can focus on different dosages of magnesium and remifentanil, as well as using longer post-operation follow-ups.



  • 1.

    Artime CA, Hagberg CA. Tracheal extubation. Respir Care. 2014; 59(6) : 991 -1002 [DOI][PubMed]

  • 2.

    Cavallone LF, Vannucci A. Review article: Extubation of the difficult airway and extubation failure. Anesth Analg. 2013; 116(2) : 368 -83 [DOI][PubMed]

  • 3.

    Asai T, Koga K, Vaughan RS. Respiratory complications associated with tracheal intubation and extubation. Br J Anaesth. 1998; 80(6) : 767 -75 [PubMed]

  • 4.

    Rassam S, Sandbythomas M, Vaughan RS, Hall JE. Airway management before, during and after extubation: a survey of practice in the United Kingdom and Ireland. Anaesthesia. 2005; 60(10) : 995 -1001 [DOI][PubMed]

  • 5.

    Miller KA, Harkin CP, Bailey PL. Postoperative tracheal extubation. Anesth Analg. 1995; 80(1) : 149 -72 [PubMed]

  • 6.

    Magnusson L, Spahn DR. New concepts of atelectasis during general anaesthesia. Br J Anaesth. 2003; 91(1) : 61 -72 [PubMed]

  • 7.

    van Zijl DH, Gordon PC, James MF. The comparative effects of remifentanil or magnesium sulfate versus placebo on attenuating the hemodynamic responses after electroconvulsive therapy. Anesth Analg. 2005; 101(6) : 1651 -5 [DOI][PubMed]

  • 8.

    Dube L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: a review. Can J Anaesth. 2003; 50(7) : 732 -46 [DOI][PubMed]

  • 9.

    Prielipp RC, Zaloga GP, Butterworth J, Robertie PG, Dudas LM, Black KW, et al. Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine. Anesthesiology. 1991; 74(6) : 973 -9 [PubMed]

  • 10.

    Shariat Moharari R, Motalebi M, Najafi A, Zamani MM, Imani F, Etezadi F, et al. Magnesium Can Decrease Postoperative Physiological Ileus and Postoperative Pain in Major non Laparoscopic Gastrointestinal Surgeries: A Randomized Controlled Trial. Anesth Pain Med. 2014; 4(1)[DOI][PubMed]

  • 11.

    Mayer DB, Miletich DJ, Feld JM, Albrecht RF. The effects of magnesium salts on the duration of epinephrine-induced ventricular tachyarrhythmias in anesthetized rats. Anesthesiology. 1989; 71(6) : 923 -8 [PubMed]

  • 12.

    Beers R, Camporesi E. Remifentanil update: clinical science and utility. CNS Drugs. 2004; 18(15) : 1085 -104 [PubMed]

  • 13.

    Michelsen LC. The pharmakokionetics of remifentanil. J Clin Anesth. 1996; 8 : 679 -82 [DOI]

  • 14.

    Scholz J, Steinfath M. [Is remifentanil an ideal opioid for anesthesiologic management in the 21st century?]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1996; 31(10) : 592 -607 [DOI][PubMed]

  • 15.

    Smith T. Ethics in medical research. 1990; : 12–49

  • 16.

    Lim SH, An DG, Choi SW, Lee SE, Kim YH, Lee JH, et al. The Comparison of Magnesium Sulfate and Remifentanil in Attenuating Hemodynamic Response to Endotracheal Intubation. Korean J Anesthesiol. 2007; 53(5) : 577 -82

  • 17.

    Kim SY, Yang SY, Na SW, Jo YY, Koh SO. Low-dose remifentanil infusion during ventilator weaning and tracheal extubation in postoperative intensive care unit patients sedated with propofol-remifentanil: a randomised clinical trial. Anaesth Intensive Care. 2012; 40(4) : 656 -62 [PubMed]

  • 18.

    Wu J, Liu L, Yang F. [Effect of small-dose remifentanil on cardiovascular response to tracheal extubation after general anesthesia]. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(9) : 1316 -8 [PubMed]

  • Copyright © 2015, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.